These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 20421744)

  • 1. Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage.
    Moreno A; Quereda C; Fortún J; Bárcena R; Pérez-Elías MJ; Casado JL; Rodríguez-Sagrado MA; Mateos ML; Blesa C; Moreno S
    AIDS; 2010 May; 24(8):1231-3. PubMed ID: 20421744
    [No Abstract]   [Full Text] [Related]  

  • 2. Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.
    Rivero-Juarez A; Lopez-Cortes LF; Girón-Gonzalez JA; Pineda JA; Rivero A;
    Lancet Infect Dis; 2014 Jan; 14(1):13-14. PubMed ID: 24355031
    [No Abstract]   [Full Text] [Related]  

  • 3. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study.
    Milazzo L; Caramma I; Mazzali C; Cesari M; Olivetti M; Galli M; Antinori S
    J Antimicrob Chemother; 2010 Apr; 65(4):735-40. PubMed ID: 20118492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pegylated interferon plus ribavirin in chronic hepatitis C. More than half of patients show a lasting response].
    Zeuzem S
    MMW Fortschr Med; 2002 Feb; 144(8):30-4. PubMed ID: 11910820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort.
    Wojcik K; Vogel M; Voigt E; Speidel N; Kalff JC; Goldmann G; Oldenburg J; Sauerbruch T; Rockstroh JK; Spengler U
    AIDS; 2007 Jun; 21(10):1363-5. PubMed ID: 17545715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
    Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
    Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
    [No Abstract]   [Full Text] [Related]  

  • 9. Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin.
    Soriano V; Labarga P; Ruiz-Sancho A; Garcia-Samaniego J; Barreiro P
    AIDS; 2006 Nov; 20(17):2225-7. PubMed ID: 17086063
    [No Abstract]   [Full Text] [Related]  

  • 10. Boceprevir for HCV in patients with HIV: where next?
    Osinusi A; Naggie S
    Lancet Infect Dis; 2013 Jul; 13(7):563-4. PubMed ID: 23768748
    [No Abstract]   [Full Text] [Related]  

  • 11. [Diabetes mellitus during interferon therapy].
    Tarabini-Castellani P; Apraiz L; Portu J; Agud JM
    Enferm Infecc Microbiol Clin; 2008 Feb; 26(2):120-1. PubMed ID: 18341927
    [No Abstract]   [Full Text] [Related]  

  • 12. Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection.
    Lissen E; Clumeck N; Sola R; Mendes-Correa M; Montaner J; Nelson M; DePamphilis J; Pessôa M; Buggisch P; Main J; Dieterich D
    AIDS; 2006 Nov; 20(17):2175-81. PubMed ID: 17086057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-alpha in treatment of chronic hepatitis C in co-infected HIV-patients in combination with ribavirin and as a pre-load therapy in treatment-naive HIV-positive patients. 8th European Conference on Clinical Aspects and Treatment of HIV Infection (8th ECCATH), 29-31 October, Athens Greece.
    Tossing G
    Eur J Med Res; 2002 Jan; 7(1):44-6. PubMed ID: 11827840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.
    Voigt E; Schulz C; Klausen G; Goelz J; Mauss S; Schmutz G; Jessen H; Weitner L; Mutz A; Schranz D; Rockstroh JK;
    J Infect; 2006 Jul; 53(1):36-42. PubMed ID: 16269184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
    Mira JA; López-Cortés LF; Merino D; Arizcorreta-Yarza A; Rivero A; Collado A; Ríos-Villegas MJ; González-Serrano M; Torres-Tortoso M; Macías J; Valera-Bestard B; Fernández-Fuertes E; Girón-González JA; Lozano F; Pineda JA;
    Antivir Ther; 2007; 12(8):1225-35. PubMed ID: 18240862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress in the treatment of hepatitis B and C co-infection in HIV patients].
    Mauss S
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():27-9. PubMed ID: 15373041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C in patients with congenital coagulation disorders.
    Katsarou O; Theodosiades G; Ioannidou P; Nomikou E; Tsevrenis B; Kouraba A; Deutch M; Terpos E; Dourakis S; Karafoulidou A
    Acta Haematol; 2008; 120(2):63-9. PubMed ID: 18827474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
    Ballesteros AL; Miró O; López S; Fuster D; Videla S; Martínez E; Garrabou G; Salas A; Côté H; Tor J; Rey-Joly C; Planas R; Clotet B; Tural C
    Antivir Ther; 2004 Dec; 9(6):969-77. PubMed ID: 15651755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.